Letter: Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab

Dermatology Online Journal

Volumn 16, Issue 8, 2010, Pages 15-

  Reddick, C L ^a   Singh, M N ^a   Chalmers, R J G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; INFLIXIMAB; METHYLPREDNISOLONE; MINOCYCLINE; PREDNISOLONE; THALIDOMIDE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; DEPIGMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FURUNCULOSIS; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; LETTER; MALE; PYODERMA GANGRENOSUM; QUALITY OF LIFE INDEX; SCAR FORMATION; SKIN ABSCESS; SKIN BIOPSY; SKIN INFLAMMATION; SKIN ULCER; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; COMORBIDITY; MIDDLE AGED; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COMORBIDITY; CYCLOSPORINE; DAPSONE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MINOCYCLINE; PREDNISOLONE; PYODERMA GANGRENOSUM; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77958131469     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007 Dec; 46(12):1287-91
2. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg. 2009 Jul-Aug; 13(4):221-5.
3. Akhras V, Sarkany R, Walsh S, Hyde N, Marsden RA. Superficial granulomatous pyoderma treated preoperatively with infliximab. Clin Exp Dermatol. 2009; 34(5):183-5
4. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006; 55(4):505-9
5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology 1994; 19: 210-216
6. Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006; 5:66-71
7. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007; 143(3):306-308
8. Wilson-Jones E and Winkelmann RK. Superficial granulomatous pyoderma: A localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 1988; 18(3):511-21
9. 3pez MA. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009 May; 145(5):580-4
10. Ah-Weng A, Langtry JA, Velangi S, Evans CD, Douglas WS. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol. 2005 30(6):669-71.
11. Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis. 1996; 57(5):315-9.
12. Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulating Crohn's disease with pyoderma gangrenosum: Two birds with one stone. World J Gastroenterol. 2009 14; 15(18):2293-5.
13. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis. 2009; 15(6):803-6.
14. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007; 157(6):1274-5.
15. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005; 152(5):1059-61.